Superworth

Prelude Therapeutics revenue PRLD

Sales by quarter and over the last twelve months, from 2024.

Last 12 months, to Jun 30, 2026
$22.4M
Latest quarter, Q2 FY26
$5.7M
Fiscal year 2025
$12.1M

Prelude Therapeutics' revenue was $22.4M over the twelve months to Jun 30, 2026, up 220% on a year earlier.

In its latest quarter, Q2 FY26, it was $5.7M.

Revenue over time

Open the interactive chart, with overlays and comparisons

Fiscal year by fiscal year

Fiscal yearRevenueChange
FY2025$12.1Mn/a
FY2024n/an/a

Each fiscal year is the twelve months to its fourth quarter.

Quarter by quarter

QuarterEndedRevenueOn a year earlierLast 12 months
Q2 FY26$5.7Mn/a$22.4M
Q1 FY26$4.6Mn/a$16.7M
Q4 FY25$5.6M+41%$12.1M
Q3 FY25$6.5M+117%$10.5M
Q2 FY25$0n/a$7M
Q1 FY25$0n/an/a
Q4 FY24$4Mn/an/a
Q3 FY24$3Mn/an/a

Against its peers

Companies in Drug Manufacturers - General nearest Prelude Therapeutics' size, closest first, today.

CompanyRevenue, 12 monthsGrowth
PRLDPrelude Therapeutics$22.4M+220% a year
NATRNatures Sunshine Products$492M+7% a year
ARVNArvinas$316.7M−15% a year
PBYIPuma Biotechnology$231.2M−3% a year
IRWDIronwood Pharmaceuticals$389.3M+26% a year
ZVRAZevra Therapeutics$136.1M+119% a year
CRMDCorMedix$462.2M+281% a year
COLLCollegium Pharmaceutical$808.2M+14% a year
ABUSArbutus Biopharma$181.7M
AMPHAmphastar Pharmaceuticals$730M+1% a year
LFVNLifevantage$182.6M−20% a year
Peer median$353M

What the revenue tells you

Total sales in the period. On the company page, quarterly bars or the trailing twelve months (TTM), which smooths seasonality.

Growing revenue with shrinking margins is a warning, not a win.

More on Prelude Therapeutics

Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.